Hanall BioPharma Q3 Operating Profit Rises 265.1% Year on Year

Bitget2026/10/28 08:44

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hanall BioPharma’s third-quarter 2026 net profit rose 924.2% year over year to KRW 3.06 billion.
Operating profit increased 265.1% from a year earlier to KRW 1.27 billion.
Revenue fell 2.2% year over year to KRW 39.91 billion.
Sequentially, operating profit dropped 77.2%; revenue declined 9.9%.
Nine-month net results swung to a KRW 15.89 billion loss from a KRW 690 million profit a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanall BioPharma Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261028800653), on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hanall BioPharma Q3 Operating Profit Rises 265.1% Year on Year

You may also like

Crypto prices